9 November 2020 - Late treatment study
Randomized Controlled Open Label Trial on the Use of Favipiravir Combined with Inhaled Interferon beta-1b in Hospitalized Patients with Moderate to Severe COVID-19 Pneumonia
et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2020.11.008 (Peer Reviewed)
Small 89 patient RCT comparing favipiravir and inhaled interferon with HCQ for moderate to severe COVID-19 pneumonia, not finding significant differences. There was no control group.
|
risk of death, 14.8% lower, RR 0.85, p = 1.00, treatment 5 of 44 (11.4%), control 6 of 45 (13.3%), NNT 51.
|
|
risk of ICU admission, 2.3% higher, RR 1.02, p = 1.00, treatment 8 of 44 (18.2%), control 8 of 45 (17.8%).
|
|
risk of no recovery, 9.6% higher, RR 1.10, p = 0.82, treatment 15 of 44 (34.1%), control 14 of 45 (31.1%).
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. |
This study is excluded in the after exclusion results of meta
analysis:
trials compares against another treatment showing significant efficacy in trials.
Khamis et al., 11/9/2020, Randomized Controlled Trial, Oman, Middle East, peer-reviewed, 11 authors, study period 22 June, 2020 - 13 August, 2020, this trial compares with another treatment - results may be better when compared to placebo, this trial uses multiple treatments in the treatment arm (combined with interferon beta-1b) - results of individual treatments may vary.
khamis
Please send us
corrections, updates, or comments. Vaccines and treatments are both
valuable and complementary. All practical, effective, and safe means
should be used. Elimination of COVID-19 is a race against viral evolution. No
treatment, vaccine, or intervention is 100% available and effective for all
current and future variants. Denying the efficacy of any method increases
mortality, morbidity, collateral damage, and the risk of endemic status. We do
not provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. WCH
and FLCCC provide
treatment protocols.